FORMULATION AND EVALUATION OF IMPLANTABLE DRUG DELIVERY SYSTEM OF TEMOZOLOMIDE BY USING HYDROPHILIC POLYMER
Keywords:Carbopol, Cross linking agent, Hydrophilic polymer, Implants, Temozolomide
Â Objective: The present research study was carried out to formulate and evaluate the implants of temozolomide using hydrophilic polymer.
Methods: Temozolomide implants were formulated using extrusion method with different grades of carbopol. The powdered blend was evaluated for micromeritic properties such as angle of repose, bulk density, tapped density, Carr's index, and Hausner's ratio. The formulated implants were analyzed for drug content uniformity, thickness, weight variation, and short-term stability study. In vitro release study of implants was performed using 0.1N hydrochloric acid, and it is maintained at 37Â°CÂ±0.5Â°C.
Results: In vitro release study demonstrated that the release rate of temozolomide from the implant matrix was a function of concentration of the polymer. As the concentration of polymer was increased, drug release from the matrix was extended. The release of drug from all implant formulations was found to be uniform and was extended over a period of 12 hrs. The implant formulations were found sterile, uniform in weight and size. The drug content was found to be in the range of 97.2-101.33%.
Conclusion: Drug interaction studies revealed that there were no chemical interactions between temozolomide and polymers used in the study. Short-term stability studies of implants revealed that implants were stable, and there were no significant changes in the physical appearance and drug content of the implant formulations. The results of the study demonstrated that implantable drug delivery system of temozolomide can be formulated using hydrophilic polymer.
Yea W, Chie W. Novel Drug Delivery System. 2nd ed. New York, NY: Marcel Dekker, Inc.; 1992. p. 269.
Sefton MV. Implantable pumps. CRC Crit Rev Biomed Eng 1987;14:201-40.
Conte U, Maggi L. A flexible technology for the linear, pulsatile and delayed release of drugs, allowing for easy accommodation of difficult in vitro targets. J Control Release 2000;64(1-3):263-8.
Lee ES, Kim SW, Kim SH, Cardinal JR, Jacobs H. Drug release from hydrogel devices with rate-controlling barriers. J Memb Sci 1980;7:293-303.
Korsmeyer RW, Peppas NA. Macromolecular and modelling aspects of swelling- controlled systems. In: Roseman TJ, Mansdorf SZ, editors. Controlled Release Delivery Systems. New York: Marcel Dekker; 1983. p. 77-90.
Yang L, Fassihi R. Modulation of diclofenac release from a totally soluble controlled release. Drug delivery system. J Control Release 1997;44:135-40.
Hildgen P, McMullen JN. A new gradient matrix: Formulation and characterization. J Control Release 1995;34:263-71.
Lu S, Anseth KS. Photopolymerization of multilaminated poly(HEMA) hydrogels for controlled release. J Control Release 1999;57(3):291-300.
Lu S, Ramirez F, Anseth K. Photopolymerized, multilaminated matrix devices with optimized non-uniform initial concentration profiles to control drug release. J Pharm Sci 2000;89:45-51.
Qiu Y, Chidambaram N, Flood K. Design and evaluation of layered diffusional matrices for zero-order sustained-release. J Control Release 1998;51(2-3):123-30.
Danckwerts M, Fassihi A. Implantable controlled release drug delivery systems: A review. Drug Dev Ind Pharm 1991;17:1465-502.
Dash AK, Cudworth GC 2nd. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods 1998;40(1):1-12.
Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci 1961;50:874-5.
Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5(12):993-6.
Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 2006;5(10):821-34.
Zaremba T, Curtin NJ. PARP inhibitor development for systemic cancer targeting anticancer agents. Med Chem 2007;7(5):515-23.
Dinca EB, Sarkaria JN, Schroeder MA, Carlson BL, Voicu R, Gupta N, et al. Bioluminescence monitoring of intracranial glioblastoma xenograft: Response to primary and salvage temozolomide therapy. J Neurosurg 2007;107(3):610-6.
Nalneesh B. Formulation and evaluation of sustained- release matrix tablets of nitrofurantoin. Int J Chem Technol Res 2013;5(1):491-501.
Lachman L, Lieberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. 3rd ed. Vargheese Publishing House; 1991.
Jameela SR, Kumary TV, Lal AV, Jayakrishnan A. Progesterone-loaded chitosan microspheres: A long acting biodegradable controlled delivery system. J Control Release 1998;52(1-2):17-24.
Islam S, Islam S, Urmi AB. Observation of the release of aspirin from gelatin-sodium alginate polymeric implant. J Chem Pharm Res 2012;4(12):5149-56.
Saparia B, Murthy RS, Solanki A. Preparation and evaluation of chloroquine phosphate microspheres using cross linked gelatin for long term drug delivery. Indian J Pharm Sci 2002;64:48-52.
Karina CR, Riesta P, Esti H. Preparation and evaluation of ciprofloxacin implants using bovine hydroxyapatite-chitosan composite and glutaraldehyde for osteomyelitis. Int J Pharm Pharm Sci 2016;8(1):45-51.
Brahmanker DM, Jaiswal SB. Biopharmaceutics and Pharmacokinetics: A Treatise. 1st ed. New Delhi: Vallabh Prakashan; 1995.
How to Cite
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.